DRL gears up for biosimilar push, consumer health growth post record FY25
Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launches, and semaglutide portfolio support long-term prospects despite Revlimid taper and reduced target prices by (...)
Site référencé: The Economic Times
The Economic Times
Harvard’s ability to enrol international students halted by Trump administration
22/05/2025
Elon Musk : Politics failed him. Can business redeem him ?
22/05/2025
Goldman Sachs buys shares worth Rs 50 crore in this smallcap stock via block deal
22/05/2025
Ashok Hinduja backs IndusInd Bank board amid fraud concerns, calls it a 'new dawn' for the lender
22/05/2025
Emkay picks JK Cement, Motilal Oswal, 2 more small & midcap stocks. 4 reasons why
22/05/2025
Kumar Mangalam Birla's Grasim gets cheapest rupee bond deal in 5 years
22/05/2025
